医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ZOLL Files with Japan’s Pharmaceuticals and Medical Devices Agency for New Indication for Intravascular Temperature Management Technology

2014年11月22日 AM01:10
このエントリーをはてなブックマークに追加


 

CHELMSFORD, Mass.

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that its Japanese subsidiary, Asahi Kasei ZOLL Medical Corp. (AZM), has filed an application with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval for the company’s Intravascular Temperature Management (IVTM™) System to be used for sudden cardiac arrest.

AZM conducted a clinical study in Japan from January 2013 to February 2014 for the indication of temperature management after resuscitation from cardiac arrest. The application for the new indication was filed based on the results of this study following consultation and advice from the PMDA. The application also includes approval for ZOLL’s QuattroTM and Icy® as new catheters for use in temperature management. Currently, only the Cool Line® catheter has approval.

“Use of temperature management for sudden cardiac arrest is recommended in numerous national guidelines including the Japan Resuscitation Council Guidelines 2010, which we think will be informative in the PMDA’s consideration of our application,” said James A. Palazzolo, President of ZOLL. “In treating resuscitated patients, there is a need for easy-to-use equipment that enables precise cooling and rewarming of core body temperature. By expanding indications for IVTM in Japan, AZM seeks to contribute to advance technology for resuscitation therapy.”

ZOLL’s IVTM system provides cooling and warming through a balloon catheter inserted into the venous system. This provides precise control of the core body temperature over surface methods by directly cooling or warming the patient’s blood as it flows through the body. This catheter is connected to the Thermogard XP® console, which circulates cold saline solution inside the catheter. Since the saline flows only within the catheter, no fluid is infused into the patient. ZOLL offers a variety of triple-lumen catheters with placement options to handle specific patient challenges. The ZOLL IVTM system is precise, efficient, and easy to use, and frees up clinical staff to attend to other patient needs. No product has been specifically approved in the U.S. for cardiac arrest.

About ZOLL Medical Corporation
ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. For more information, visit www.zoll.com.

About Asahi Kasei
The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 29,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.

Copyright © 2014 ZOLL Medical Corporation. All rights reserved. Cool Line, Icy, Quattro, Thermogard XP, and ZOLL are trademarks and/or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All trademarks are the property of their respective owners.

CONTACT

ZOLL Medical Corporation
Diane Egan, +1 978-421-9637
degan@zoll.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作